Evelo Biosciences, Inc. announced that Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in first quarter and second quarter of 2023. Phase 2 data for EDP2939 in psoriasis expected in second half of 2023. EDP1815 in Psoriasis: Moving Towards Registration Trials.

The Company is currently engaging with health authorities in the United States and Europe to solicit feedback on its proposed plans for advancing EDP1815 into registrational trials in psoriasis. Evelo anticipates feedback by the end of 2022. EDP1815 in Atopic Dermatitis: Phase 2 Data Expected in first quarter and second quarter of 2023.· Recruitment for the first three cohorts in the Phase 2 trial of EDP1815 in atopic dermatitis is on-schedule.

As previously shared, Evelo has added a fourth cohort to the on-going Phase 2 trial. Patients in this cohort will receive one capsule of EDP1815 with a faster release profile once daily. EDP2939 - Inflammation: First Orally Delivered Microbial Extracellular Vesicle (EV); Phase 1/2 Data in Psoriasis.

Expected in 2H 2023: Initiation of a Phase 1/2 trial in healthy volunteers and patients with psoriasis in third quarter of 2022, with dosing expected to commence in fourth quarter of 2022.